Galectin Therapeutics
GALT
GALT
60 hedge funds and large institutions have $10.5M invested in Galectin Therapeutics in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 14 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
more funds holding
Funds holding: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
29% less capital invested
Capital invested by funds: $14.8M → $10.5M (-$4.35M)
43% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 14
Holders
60
Holding in Top 10
–
Calls
$92K
Puts
$18K
Top Buyers
| 1 | +$236K | |
| 2 | +$28.8K | |
| 3 | +$22.9K | |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$10.4K |
| 5 |
Millennium Management
New York
|
+$9.62K |
Top Sellers
| 1 | -$85.1K | |
| 2 | -$29.8K | |
| 3 | -$17.7K | |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$11.6K |
| 5 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$8.28K |